2篇
您的检索式：作者名="Dachuan Lin"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients显示文摘Dear Editor,In late December 2019,an outbreak of severe pneumonia caused by an unknown etiological agent was initially reported in Wuhan,China,and then quickly spread throughout China and even abroad(Zhu et al.,2020).Swift control measures and etiological investigations were conducted by the Chinese government,physicians and researchers,and by using high throughput sequencing and virological testing,the mysterious pneumonia pathogen was shown to be a novel coronavirus(SARS-CoV-2)capable of person-to-person transmission(Zhu et al.,2020).Coronaviruses are a group of non-segmented,enveloped and positive-sense RNA viruses that belong to the subfamily of Coronavirinae in the family of Coronavirdiae and order of Nidovirales. | Dachuan Lin Lei Liu Mingxia Zhang Yunlong Hu Qianting Yang Jiubiao Guo Yongchao Guo Youchao Dai Yuzhong Xu Yi Cai Xinchun Chen Zheng Zhang Kaisong Huang | 2020 | Science China(Life Sciences)2020，63，4： | 6 |
| 2 | Weakened humoral immune responses of inactivated SARS-CoV-2 vaccines in patients with solid tumors显示文摘Dear Editor Coronavirus disease 19(COVID-19),caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),remains a pandemic.Cancer patients have a higher risk of poor outcomes for SARS-CoV-2 infection than the general population[1].Vaccines were shown to effectively prevent SARS-CoV-2 infection,severe disease progression,and mortality.Inactivated SARS-CoV-2 vaccines(BBIBPCorV and CoronaVac)have been approved and widely used in China,with the former shown to be more effective than the latter[2].Hence,there is an urgent need to investigate the safety and humoral immune responses of inactivated vaccines in cancer patients. | Zhiwei Chen Peng Zhu Zuojin Liu Bin Zhu Guobing Yin Jia Ming Rui Song Qingbo Pan Tong Li Xingwei Jiang Bing Wang Shuaibin Liu Hongxing Cai Jingjie Wang Yuling Han Zijing Lin Yang Hong Min Chen Mingli Peng Lina Hu Dachuan Cai Hong Ren | 2023 | Cancer Communications2023，43，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员